Picture of Dermata Therapeutics logo

DRMA Dermata Therapeutics Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Annual cashflow statement for Dermata Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2021
December 31st
2022
December 31st
2023
December 31st
2024
December 31st
2025
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-7.9-9.61-7.79-12.3-7.56
Depreciation
Non-Cash Items1.920.930.5220.6580.144
Other Non-Cash Items
Changes in Working Capital0.29-0.1540.8640.467-0.343
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Cash from Operating Activities-5.69-8.83-6.41-11.2-7.76
Financing Cash Flow Items-0-0.001-0.051
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities164.287.616.8912.1
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash10.3-4.561.2-4.284.36